Advertisement
UK markets open in 58 minutes
  • NIKKEI 225

    39,189.09
    +384.44 (+0.99%)
     
  • HANG SENG

    18,121.12
    +93.41 (+0.52%)
     
  • CRUDE OIL

    81.69
    +0.06 (+0.07%)
     
  • GOLD FUTURES

    2,337.70
    -6.70 (-0.29%)
     
  • DOW

    39,411.21
    +260.91 (+0.67%)
     
  • Bitcoin GBP

    48,053.91
    -1,034.23 (-2.11%)
     
  • CMC Crypto 200

    1,267.79
    +18.67 (+1.49%)
     
  • NASDAQ Composite

    17,496.82
    -192.54 (-1.09%)
     
  • UK FTSE All Share

    4,514.76
    +23.84 (+0.53%)
     

Tempest to Participate in Upcoming Investor Conferences

Tempest Therapeutics
Tempest Therapeutics

BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that management will participate in the following upcoming investor conferences:

  • TD Cowen's 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET

  • Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5, 2024 at 4:00 p.m. ET

To access the live or archived recording of the discussions, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

ADVERTISEMENT

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

 

i If approved by the FDA